Cited by 28Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and TreatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies

Open access

Abstract

Among individuals with dementia with Lewy bodies, pathologic correlates of clinical course include the presence and extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease. The objectives of this study are to determine (i) whether 18F-fluorodeoxyglucose PET signature patterns of dementia with Lewy bodies are associated with the extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease and (ii) whether these 18F-fluorodeoxyglucose pattern(s) are associated with clinical course in dementia with Lewy bodies. Two groups of participants were included: a pathology-confirmed subset with Lewy body disease (n = 34) and a clinically diagnosed group of dementia with Lewy bodies (n = 87). A subset of the clinically diagnosed group was followed longitudinally (n = 51). We evaluated whether 18F-fluorodeoxyglucose PET features of dementia with Lewy bodies (higher cingulate island sign ratio and greater occipital hypometabolism) varied by Lewy body disease subtype (transitional versus diffuse) and Braak neurofibrillary tangle stage. We investigated whether the PET features were associated with the clinical trajectories by performing regression models predicting Clinical Dementia Rating Scale Sum of Boxes. Among autopsied participants, there was no difference in cingulate island sign or occipital hypometabolism by Lewy body disease type, but those with a lower Braak tangle stage had a higher cingulate island sign ratio compared to those with a higher Braak tangle stage. Among the clinically diagnosed dementia with Lewy bodies participants, a higher cingulate island ratio was associated with better cognitive scores at baseline and longitudinally. A higher 18F-fluorodeoxyglucose PET cingulate island sign ratio was associated with lower Braak tangle stage at autopsy, predicted a better clinical trajectory in dementia with Lewy body patients and may allow for improved prognostication of the clinical course in this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/braincomms/fcaa040

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 25

  1. Avants, 2011, A reproducible evaluation of ANTs similarity metric performance in brain image registration, NeuroImage, 54, 2033, 10.1016/j.neuroimage.2010.09.025 · DOI · Paper page
  2. Berg, 1988, Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment, Ann Neurol, 23, 477, 10.1002/ana.410230509 · DOI
  3. Boeve, 2011, Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort, Sleep Med, 12, 445, 10.1016/j.sleep.2010.12.009 · DOI
  4. Coughlin, 2018, Cognitive and pathological influences of tau pathology in Lewy body disorders, Ann Neurol, 85, 259, 10.1002/ana.25392 · DOI
  5. Ferman, 2004, DLB fluctuations, Specific features that reliably differentiate DLB from AD and normal aging. Neurology, 62, 181
  6. Fujishiro, 2008, Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases, J Neuropathol Exp Neurol, 67, 649, 10.1097/NEN.0b013e31817d7a1d · DOI
  7. Graff-Radford, 2017, Duration and pathologic correlates of Lewy body disease, JAMA Neurol, 74, 310, 10.1001/jamaneurol.2016.4926 · DOI
  8. Graff-Radford, 2012, Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies, Brain, 135, 2470, 10.1093/brain/aws173 · DOI
  9. Graff-Radford, 2016, Predicting survival in dementia with Lewy bodies with hippocampal volumetry, Mov Disord, 31, 989, 10.1002/mds.26666 · DOI
  10. Hyman, 2012, National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease, Alzheimers Dement, 8, 1, 10.1016/j.jalz.2011.10.007 · DOI · Paper page
  11. Iizuka, 2016, Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies, Ann Nucl Med, 30, 421, 10.1007/s12149-016-1076-9 · DOI
  12. Imabayashi, 2017, Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer’s disease using brain perfusion SPECT, Ann Nucl Med, 31, 536, 10.1007/s12149-017-1181-4 · DOI
  13. Irwin, 2017, Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis, Lancet Neurol, 16, 55, 10.1016/S1474-4422(16)30291-5 · DOI
  14. Kantarci, 2012, Multimodality imaging characteristics of dementia with Lewy bodies, Neurobiol Aging, 33, 2091, 10.1016/j.neurobiolaging.2011.09.024 · DOI
  15. Lemstra, 2017, Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies, J Neurol Neurosurg Psychiatry, 88, 113, 10.1136/jnnp-2016-313775 · DOI
  16. Lim, 2009, The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. Journal of nuclear medicine: official publication, Soc Nucl Med, 50, 1638, 10.2967/jnumed.109.065870 · DOI · Paper page
  17. McKeith, 2017, Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium, Neurology, 89, 88, 10.1212/WNL.0000000000004058 · DOI · Paper page
  18. Mirra, 1991, The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), Part II standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology, 41, 479
  19. Morris, 1993, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology, 43, 2412, 10.1212/WNL.43.11.2412-a · DOI · Paper page
  20. Olichney, 1998, Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease, Neurology, 51, 351, 10.1212/WNL.51.2.351 · DOI
  21. Patterson, 2019, Neuropathological changes in dementia with Lewy bodies and the cingulate island sign, J Neuropathol Exp Neurol, 78, 717, 10.1093/jnen/nlz047 · DOI
  22. Rongve, 2014, Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer’s dementia, Int J Geriatr Psychiatry, 29, 392, 10.1002/gps.4015 · DOI
  23. Schwarz, 2017, The mayo clinic adult lifespan template: better quantification across the lifespan, Alzheimers Dement, 13, P792, 10.1016/j.jalz.2017.06.1071 · DOI
  24. Tzourio-Mazoyer, 2002, Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, NeuroImage, 15, 273, 10.1006/nimg.2001.0978 · DOI · Paper page
  25. Williams, 2006, Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease, Neurology, 67, 1935, 10.1212/01.wnl.0000247041.63081.98 · DOI · Paper page

Cited by

Sorted by citations

See all 28

Metadata

Authors
Graff-Radford, J., Lesnick, T. G., Savica, R., Chen, Q., Ferman, T. J., Przybelski, S. A., Jones, D. T., Senjem, M. L., Gunter, J. L., Kremers, W. K., Jack, C. R., Lowe, V. J., Petersen, R. C., Knopman, D. S., Boeve, B. F., Murray, M. E., Dickson, D. W., & Kantarci, K.
Affiliations
  • Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
  • Mayo Clinic (US)
  • Mayo Clinic in Florida (US)
Venue
Brain Communications
Published
2020-01-01
Volume
2
Issue
1
Pages
fcaa040-fcaa040
ISSN
2632-1297 (ISSN-L)
OpenAlex
W3015874802
Cited by
28
References
2
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 5 · 2021: 5
FWCI
3.10
Type
journal article
Language
en
Open access
Locations
  • Brain Communications (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Center for Research Resources (C06-RR018898)
  • National Institute on Aging (R01-AG050603, P50-AG016574, U01-AG006786)
  • Mangurian Foundation for Lewy Body Research
  • Elsie and Marvin Dekelboum Family Foundation
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
dementia with Lewy bodies, 18F-FDG PET, Alzheimer's disease pathology, clinical course, outcome prediction, Clinical Dementia Rating

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review